Related Experiment Video
Updated: Oct 19, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Trigger-based adaptive proton therapy and changes in target coverage and cardiac dose in esophageal cancer
Vlad Badiu1, Esther Kneepkens1, Dominique Reijtenbagh1
1Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, Netherlands.
Background And Purpose:
Inter-fractional anatomical variations during proton therapy for esophageal cancer may compromise target coverage and increase dose to surrounding organs. Adaptive replanning can mitigate these effects, but its cumulative dose-based and clinical impact remains insufficiently characterized. We evaluated offline adaptive intensity-modulated proton therapy (IMPT) triggered by target underdose or cardiac overdose using deformable dose accumulation.
Materials And Methods:
A retrospective cohort of 192 esophageal cancer patients treated with IMPT was analyzed. Eighty-five underwent adaptive replanning and 107 were treated non-adaptively. Dose accumulation was performed by assigning each fraction to the closest weekly repeat computed tomography (CT) scan and deformably mapping doses to the planning CT. Accumulated doses from adapted and non-adapted plans were compared for internal target volume (ITV) and gross tumor volume (GTV) coverage, target hotspots, heart and lung dose, and normal tissue complication probability (NTCP) for 2-year post-treatment mortality.
Results:
Compared with the non-adaptive treatment scenario, the adaptive scenario increased ITV D98% by 1.9 percentage points (pp) and GTV D98% by 0.8 pp. in the target underdose subgroup. In the cardiac overdose subgroup, mean heart dose decreased by 1.0 Gy and heart V40Gy by 1.7 pp., with no increase in mean lung dose. NTCP for 2-year post-treatment mortality decreased by 1.5 pp. in this subgroup.
Conclusions:
Trigger-based adaptive IMPT improved cumulative target coverage and cardiac sparing without increasing lung dose. Target underdose and cardiac overdose triggers provided complementary benefits, supporting their use in structured adaptive replanning.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Tumor Immunotherapy

